Results 51 to 60 of about 8,071 (195)

Inclusion body myositis. [PDF]

Journal of Neurology, Neurosurgery & Psychiatry, 1996
Since the early description of cases of inflammatory myopathy with unusual filamentous inclusions in muscle fibres inclusion body myotis has come to be recognised as a major form of idiopathic inflammatory with distinctive clinical and pathological features which accounts for up to a third of patients with inflammatory myopathy see in a neuromuscular ...
Garlepp, M.J., Mastaglia, F.L.
openaire   +2 more sources

Balloon Dilation in Sporadic Inclusion Body Myositis Patients with Dysphagia

Clinical Medicine Insights: Case Reports, 2013
Here, we describe balloon catheter dilation at the upper esophageal sphincter (UES) in three sporadic inclusion body myositis (s-IBM) patients with dysphagia.
Ken-ya Murata, Ken Kouda, Fumihiro Tajima, Tomoyoshi Kondo   +3 more
doaj   +2 more sources

Integrated Clinical and Proteomic Profiling of CD19 Chimeric Antigen Receptor T Cell Therapy in Progressive Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia, Wanyi Lin, Zhangyi Zhao, Fenglin Wu, Chaoyu Gu, Yuankai Sun, Zhe Ding, Chang Wei, Xinyu Li, Cuiwei Xie, Peng Xia, Zhen Xia, Xuesong Liu, Shaoying Yang, Chunyan Zhang, Hanlin Yin, Liangjing Lu   +16 more
wiley   +1 more source

Role of noninvasive ventilation in perioperative patients with neuromuscular disease: a clinical case

Brazilian Journal of Anesthesiology, 2016
The inclusion body myositis is an inflammatory myopathy that leads to chronic muscle inflammation associated with muscle weakness. It is characterized by a restrictive ventilatory syndrome requiring ventilatory support under non-invasive ventilation. The
Ana Marinho, Mario José Guimarães, Neusa Cristina Ribeiro Lages, Carlos Correia   +3 more
doaj   +3 more sources

Anesthetic management of a hydrocephalus patient with inclusion body myositis

JA Clinical Reports, 2017
Inclusion body myositis (IBM) is an inflammatory muscle disease characterized by slowly progressive muscle weakness and wasting, especially affecting proximal leg and distal arm.
Daiki Takekawa, Hirotaka Kinoshita, Tomoyuki Kudo, Masato Kitayama, Tetsuya Kushikata, Kazuyoshi Hirota   +5 more
doaj   +1 more source

Treatment‐Related Adverse Events and Health‐Related Quality of Life Associated With Immune Checkpoint Inhibitor Treatment for Mucosal Head and Neck Squamous Cell Carcinoma: A Scoping Review

Head &Neck, EarlyView.
ABSTRACT Background Supportive care needs of patients receiving immune checkpoint inhibitors (ICIs) for head and neck squamous cell carcinoma (HNSCC) are ill‐defined. Hence, known treatment‐related adverse events (TRAEs) and health‐related quality of life (HRQoL) associated with ICI treatment for HNSCC were examined to inform future supportive care ...
N. D. O'Donnell, E. C. Ward, L. R. Wishart, R. Perera, C. Barrett, K. A. Edmiston, E. Mitchell, A. Pigott, R. Pitt, K. Russell, B. A. Chan, R. Ladwa   +11 more
wiley   +1 more source

Th1 response and systemic treg deficiency in inclusion body myositis.

PLoS ONE, 2014
ObjectiveSporadic inclusion body myositis (sIBM), the most frequent myositis in elderly patients, is characterized by the presence muscle inflammation and degeneration.
Yves Allenbach, Wahiba Chaara, Michelle Rosenzwajg, Adrien Six, Nicolas Prevel, Federico Mingozzi, Julia Wanschitz, Lucile Musset, Jean-Luc Charuel, Bruno Eymard, Benoit Salomon, Charles Duyckaerts, Thierry Maisonobe, Odile Dubourg, Serge Herson, David Klatzmann, Olivier Benveniste   +16 more
doaj   +1 more source

Tolerability of Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: A Real‐World Study

International Journal of Cancer, EarlyView.
ABSTRACT Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate‐577 trial, Grade 3–5 nivolumab‐related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real‐world data on immunotherapy‐related adverse
Michelle Koops van ’t Jagt, Anniek Strijdhorst, Tamara Jessica Huizer, Esther Albertien Kleibeuker, Sarah Derks, Bianca Mostert, Hanneke van Laarhoven, Jacco Juri de Haan   +7 more
wiley   +1 more source

Inclusion Body Myositis presenting with macroglossia: A diagnostic challenge

Advances in Oral and Maxillofacial Surgery
Patients with Inclusion Body Myositis (IBM) may present with symptoms such as dysarthria and dysphagia, often before a formal diagnosis. Increased awareness and understanding of IBM among clinicians can help identify early signs, leading to timely ...
Aaron Patel, Suresh Shetty
doaj   +1 more source

Hypertransaminasemia in hospitalized children: Insights from a National Multicenter Study by the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Hypertransaminasemia is a frequent finding in hospitalized children with common pediatric illnesses, often considered a transitory phenomenon associated with systemic inflammation/injury. This study aims to assess the prevalence and causes of incidentally detected hypertransaminasemia in children admitted to general pediatric units ...
Angelo Di Giorgio, Giusy Ranucci, Pietro Aliberti, Carmela Pia Senatore, Camilla Calì, Angelo Mazza, Francesca Sbravati, Patrizia Alvisi, Maurizio Giuseppe Fuoti, Ilaria Rochira, Antonio Marseglia, Maria Rosa Pastore, Annalisa Madeo, Alessandro La Rosa, Federica Ferrari, Fortunata Sabrina Civitelli, Valentina Maffini, Icilio Dodi, Serena della Femina, Andrea Colangelo, Lorenzo D'Antiga, Claudia Mandato   +21 more
wiley   +1 more source